Pipeline

OVERVIEW

Our current pipeline aims to disrupt existing treatment paradigms by combining new molecular entities with best-in-class potential and a leading-edge platform targeting medical dermatology, autoimmune and neuroinflammatory diseases.

PIPELINE

Program Indication(s) Discovery Preclinical Phase I Phase II Phase III Approved Next Milestone
Sofpironium Bromide
Retrometabolic Anticholinergic		 Primary Axillary
Hyperhidrosis
Ph3 Data: Q4/2021
Commercialized in Japan: ECCLOCK® Gel 5%
Primary Palmoplantar
Hyperhidrosis		 Ph1 Data
BBI-02
DYRK1A inhibitor
  • Autoimmune Diseases
  • Atopic Dermatitis
  • Rheumatoid Arthritis
  • Type 1 Diabetes
  • Others
Ph1 Initiation: 2022
BBI-03
DYRK1A inhibitor
  • Autoimmune Dermatology
  • Atopic Dermatitis
  • Psoriasis
  • Others
Formulation
Development: 2022
Next Generation
DYRK1A inhibitor		 Neuroinflammatory
& Other Diseases
Lead
Selection: 2022
Topical Oral

Click on image to enlarge it